Daily BriefsECM

Daily Brief ECM: Ascentage Pharma Top-Up Placement – Past Deals Didn’t Done Well and more

In today’s briefing:

  • Ascentage Pharma Top-Up Placement – Past Deals Didn’t Done Well, Stock up a Lot but Sector Is Strong
  • Travel Food Services IPO Trading – Decent Anchor; Subdued Overall Demand
  • Anthem Biosciences IPO – Thoughts on Peer Comp and Valuation
  • Pre-IPO Busy Ming Group – Concerns Behind the High Growth
  • MegaRobo Technologies IPO Preview: AI-Driven Robotics Unicorn With Strong IP Moat In Automation
  • McGraw Hill, Inc. (MH): Legacy Education Company Sets Terms, Down-Round from 2021 Purchase
  • NIQ Global Intelligence Plc (NIQ): Advent-Backed, Consumer Intelligence Company Sets Terms for IPO
  • Kasumigaseki Hotel REIT Pre-IPO: Young Hotel Assets and Improving Economics


Ascentage Pharma Top-Up Placement – Past Deals Didn’t Done Well, Stock up a Lot but Sector Is Strong

By Sumeet Singh

  • Ascentage Pharma Group Corp (6855 HK) (AP) aims to raise around US$196m via  top-up placement.
  • The company has undertaken a number of deals in the past, with none of the deals having done well. Although stock momentum has been strong this year.
  • In this note, we will talk about the deal dynamics and run the deal through our ECM framework.

Travel Food Services IPO Trading – Decent Anchor; Subdued Overall Demand

By Akshat Shah

  • Travel Food Services Ltd (1450229D IN) raised about US$233m in its India IPO.
  • Travel Food Services Limited (TFS) operates a network of travel quick service restaurants (Travel QSRs) and private lounges in airports.
  • We have looked at the company’s past performance and valuations in our previous notes. In this note, we will talk about the trading dynamics.

Anthem Biosciences IPO – Thoughts on Peer Comp and Valuation

By Akshat Shah

  • Anthem Biosciences (1234D IN) is looking to raise about US$397m in its India IPO.
  • Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.
  • We have looked at the company’s past performance in our previous notes. In this note, we will talk about the peer comp and IPO valuations.

Pre-IPO Busy Ming Group – Concerns Behind the High Growth

By Xinyao (Criss) Wang

  • BUSY MING operates under the franchise model, under which franchisees and BUSY MING form collaboration and a virtuous cycle, benefiting from the ecological logic of high turnover.
  • However, the potential risk is increasing homogeneous competition. Price wars and competitors’ rapid expansion would further squeeze the profit margin of BUSY MING and lead to market oversaturation.
  • The current high growth may not sustain.BUSY MING clearly hopes to successfully IPO during the current peak period of performance, but investors may face a decline in performance after IPO.

MegaRobo Technologies IPO Preview: AI-Driven Robotics Unicorn With Strong IP Moat In Automation

By Andrei Zakharov

  • MegaRobo Technologies, AI & robotics unicorn with focus on lab automation in life sciences and intelligent manufacturing, files to list IPO on Hong Kong Stock Exchange.
  • Founder led, AI native company was backed by Sinovation Ventures, Goldman Sachs, Asia Investment Capital, Robert Bosch Venture Capital, GGV Capital, and Joy Capital, among others.
  • The business is growing fast and increases the number of use cases across new verticals. However, negative free cash flows and operating losses are a headwind.

McGraw Hill, Inc. (MH): Legacy Education Company Sets Terms, Down-Round from 2021 Purchase

By IPO Boutique

  • McGraw Hill is offering 24.39mm shares at $19.00-$22.00 equating to a market cap of $3.6b-$4.2b and is scheduled to debut on July 24th.
  • The company is backed by Platinum Equity, a private equity firm that acquired the company from Apollo Global Management for approximately $4.5 billion in August 2021. 
  • Private Equity IPOs are to be a theme in the 2H of 2025 and McGraw Hill will be a test for the market based on the financial profile.

NIQ Global Intelligence Plc (NIQ): Advent-Backed, Consumer Intelligence Company Sets Terms for IPO

By IPO Boutique

  • NIQ Global Intelligence plc is offering 50.0mm shares at $20.00-$24.00 equating to a market cap of $5.9b-$7.1b and is scheduled to debut on July 23rd.
  • If successful, this will be the third IPO to raise $1 billion in 2025. 
  • NIQ Global Intelligence has a boat-load of debt, is private-equity backed but has a growth profile that is promising. We believe price sensitivity may play a role.

Kasumigaseki Hotel REIT Pre-IPO: Young Hotel Assets and Improving Economics

By Nicholas Tan


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars